Company / Total Debt
Jazz Pharmaceuticals Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$5.4B
FY2025
5-year range
$5.4B / $6.1B
FY2021-FY2025
Trend
-12.3%
vs FY2024
Sector context
#16 of 83
Health Care
What the data says
Jazz Pharmaceuticals's total debt of $5.4B is higher than 81% of companies in the Health Care sector (FY2025). Total Debt has fluctuated over the past 10 years, ranging from $1.6B in FY2017 to $6.1B in FY2024.
Based on SEC 10-K filings.
$5.4B in FY2025 with a 5-year CAGR of +20.7%. Top quartile in the Health Care sector.
Improved from $5.7B to $5.4B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -2.2%
- 5-Year CAGR
- +20.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 83This company $5.4B Sector average $6.2B
▼
-12.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.7%, indicating consistent growth.
- In FY2025, total debt decreased 12.3% year-over-year.
- Ranks #16 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.4B | -12.3% |
| FY2024 | $6.1B | +6.9% |
| FY2023 | $5.7B | -0.2% |
| FY2022 | $5.7B | -5.4% |
| FY2021 | $6.0B | +188.8% |
| FY2020 | $2.1B | +30.3% |
| FY2019 | $1.6B | +0.7% |
| FY2018 | $1.6B | +1.0% |
| FY2017 | $1.6B | -22.1% |
| FY2016 | $2.0B | +70.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026